search button

Tertiary cytoreduction in the setting of recurrent ovarian cancer (Review)

  • Authors:
    • Nasuh Utku Dogan
    • Achim Schneider
    • Vito Chiantera
    • Selen Dogan
    • Polat Dursun

  • View Affiliations

  • Published online on: July 4, 2013     https://doi.org/10.3892/ol.2013.1445
  • Pages: 642-647
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Ovarian cancer is the most lethal gynecological malignancy, with aggressive surgical debulking and adjuvant chemotherapy as the main treatment modalities. Optimal debulking during the primary surgery is significantly correlated with prolonged survival. As surgical techniques and chemotherapeutic agents improve, more patients with prolonged survival may face secondary and tertiary recurrences. The role of surgical debulking in secondary cytoreduction (SC) is not clearly defined and is based on retrospective series. The treatment of patients with primary or secondary recurrences generally consists of second‑line chemotherapy, but may be performed on medically fit patients in certain circumstances. A limited number of studies concerning tertiary cytoreduction (TC) in cases of secondary recurrences have been published. In these studies, conventional prognostic factors for SC, including ascites, an advanced International Federation of Gynecology and Obstetrics (FIGO) stage and/or peritoneal carcinomatosis, did not apply to TC, but the post‑operative residual tumor load was significant in determining the prognosis. A limited number of patients with completely‑resectable tumors may have an opportunity for a maximal cytoreduction in these circumstances. TC appears to result in a favorable outcome and moderate complication rates. The surgery is an available option for patients with recurrence, in whom a complete tumor resection may be achieved.
View Figures
View References

Related Articles

Journal Cover

September 2013
Volume 6 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Dogan NU, Schneider A, Chiantera V, Dogan S and Dursun P: Tertiary cytoreduction in the setting of recurrent ovarian cancer (Review). Oncol Lett 6: 642-647, 2013.
APA
Dogan, N.U., Schneider, A., Chiantera, V., Dogan, S., & Dursun, P. (2013). Tertiary cytoreduction in the setting of recurrent ovarian cancer (Review). Oncology Letters, 6, 642-647. https://doi.org/10.3892/ol.2013.1445
MLA
Dogan, N. U., Schneider, A., Chiantera, V., Dogan, S., Dursun, P."Tertiary cytoreduction in the setting of recurrent ovarian cancer (Review)". Oncology Letters 6.3 (2013): 642-647.
Chicago
Dogan, N. U., Schneider, A., Chiantera, V., Dogan, S., Dursun, P."Tertiary cytoreduction in the setting of recurrent ovarian cancer (Review)". Oncology Letters 6, no. 3 (2013): 642-647. https://doi.org/10.3892/ol.2013.1445